» Articles » PMID: 21146621

Predictive Markers for AD in a Multi-modality Framework: an Analysis of MCI Progression in the ADNI Population

Overview
Journal Neuroimage
Specialty Radiology
Date 2010 Dec 15
PMID 21146621
Citations 180
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's Disease (AD) and other neurodegenerative diseases affect over 20 million people worldwide, and this number is projected to significantly increase in the coming decades. Proposed imaging-based markers have shown steadily improving levels of sensitivity/specificity in classifying individual subjects as AD or normal. Several of these efforts have utilized statistical machine learning techniques, using brain images as input, as means of deriving such AD-related markers. A common characteristic of this line of research is a focus on either (1) using a single imaging modality for classification, or (2) incorporating several modalities, but reporting separate results for each. One strategy to improve on the success of these methods is to leverage all available imaging modalities together in a single automated learning framework. The rationale is that some subjects may show signs of pathology in one modality but not in another-by combining all available images a clearer view of the progression of disease pathology will emerge. Our method is based on the Multi-Kernel Learning (MKL) framework, which allows the inclusion of an arbitrary number of views of the data in a maximum margin, kernel learning framework. The principal innovation behind MKL is that it learns an optimal combination of kernel (similarity) matrices while simultaneously training a classifier. In classification experiments MKL outperformed an SVM trained on all available features by 3%-4%. We are especially interested in whether such markers are capable of identifying early signs of the disease. To address this question, we have examined whether our multi-modal disease marker (MMDM) can predict conversion from Mild Cognitive Impairment (MCI) to AD. Our experiments reveal that this measure shows significant group differences between MCI subjects who progressed to AD, and those who remained stable for 3 years. These differences were most significant in MMDMs based on imaging data. We also discuss the relationship between our MMDM and an individual's conversion from MCI to AD.

Citing Articles

Hybrid multi-modality multi-task learning for forecasting progression trajectories in subjective cognitive decline.

Yu M, Fang Y, Liu Y, Bozoki A, Xiao S, Yue L Neural Netw. 2025; 186:107263.

PMID: 39985974 PMC: 11893250. DOI: 10.1016/j.neunet.2025.107263.


Evaluating conversion from mild cognitive impairment to Alzheimer's disease with structural MRI: a machine learning study.

Vecchio D, Piras F, Natalizi F, Banaj N, Pellicano C, Piras F Brain Commun. 2025; 7(1):fcaf027.

PMID: 39886067 PMC: 11780885. DOI: 10.1093/braincomms/fcaf027.


Frontiers and hotspots evolution in mild cognitive impairment: a bibliometric analysis of from 2013 to 2023.

He C, Hu X, Wang M, Yin X, Zhan M, Li Y Front Neurosci. 2024; 18:1352129.

PMID: 39221008 PMC: 11361971. DOI: 10.3389/fnins.2024.1352129.


Autoencoder to Identify Sex-Specific Sub-phenotypes in Alzheimer's Disease Progression Using Longitudinal Electronic Health Records.

Meng W, Xu J, Huang Y, Wang C, Song Q, Ma A medRxiv. 2024; .

PMID: 39040206 PMC: 11261930. DOI: 10.1101/2024.07.07.24310055.


Predicting the Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Graph Frequency Bands and Functional Connectivity-Based Features.

Zamani J, Talesh Jafadideh A Res Sq. 2024; .

PMID: 38947050 PMC: 11213162. DOI: 10.21203/rs.3.rs-4549428/v1.


References
1.
Thompson P, Mega M, Woods R, Zoumalan C, Lindshield C, Blanton R . Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb Cortex. 2000; 11(1):1-16. DOI: 10.1093/cercor/11.1.1. View

2.
Piefke M, Weiss P, Zilles K, Markowitsch H, Fink G . Differential remoteness and emotional tone modulate the neural correlates of autobiographical memory. Brain. 2003; 126(Pt 3):650-68. DOI: 10.1093/brain/awg064. View

3.
Duchesne S, Caroli A, Geroldi C, Barillot C, Frisoni G, Collins D . MRI-based automated computer classification of probable AD versus normal controls. IEEE Trans Med Imaging. 2008; 27(4):509-20. DOI: 10.1109/TMI.2007.908685. View

4.
Reiman E, Caselli R, Yun L, Chen K, Bandy D, Minoshima S . Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996; 334(12):752-8. DOI: 10.1056/NEJM199603213341202. View

5.
Walhovd K, Fjell A, Brewer J, McEvoy L, Fennema-Notestine C, Hagler Jr D . Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol. 2010; 31(2):347-54. PMC: 2821467. DOI: 10.3174/ajnr.A1809. View